Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Wave Life Sciences to host conference call » 10:04
09/28/22
09/28
10:04
09/28/22
10:04
WVE

Wave Life Sciences

$3.77 /

+0.105 (+2.87%)

Management holds a…

Management holds a conference call entitled, "Spotlight on RNA Editing for AATD" on September 28 at 10 am. Webcast Link

ShowHide Related Items >><<
WVE Wave Life Sciences
$3.77 /

+0.105 (+2.87%)

WVE Wave Life Sciences
$3.77 /

+0.105 (+2.87%)

05/13/22 H.C. Wainwright
Wave Life Sciences price target lowered to $8 from $10 at H.C. Wainwright
03/03/22 Stifel
Wave Life Sciences price target lowered to $3 from $6 at Stifel
WVE Wave Life Sciences
$3.77 /

+0.105 (+2.87%)

Over a week ago
Hot Stocks
Wave Life Sciences announces update from Phase 1b/2a SELECT-HD trial » 07:35
09/20/22
09/20
07:35
09/20/22
07:35
WVE

Wave Life Sciences

$3.42 /

+0.19 (+5.88%)

Wave Life Sciences…

Wave Life Sciences announced a positive update to the ongoing Phase 1b/2a SELECT-HD clinical trial of WVE-003, the company's clinical candidate for Huntington's disease. SELECT-HD is an adaptive trial designed to rapidly optimize dose level and frequency based on early indicators of target engagement. The trial update announced is being driven by the observation of reductions in mutant huntingtin protein in cerebrospinal fluid after study participants received either a single 30 or 60 mg dose of WVE-003. Additionally, wild-type huntingtin protein was preserved, which appears consistent with allele-selectivity. Eighteen participants have been dosed in the SELECT-HD trial. Participants enrolled at 30 mg, 60 mg and placebo had adequate follow-up to day 85 for biomarker analysis. At the time of analysis, none of the participants dosed with 90 mg had reached day 85 so this cohort is not included in the biomarker analysis. Key observations include:Single doses of WVE-003 up to 90 mg appeared generally safe and well-tolerated; Adverse events were balanced across treatment groups, including placebo, and all were mild to moderate in intensity; No serious adverse events were observed; No participants discontinued from the study; Among participants in the 30 and 60 mg WVE-003 cohorts, the mean reduction in CSF mHTT from baseline was 22% at 85 days following a single dose ; The difference in the mean reduction in CSF mHTT compared to placebo was 35% at 85 days post-single dose; For these analyses, the 30 and 60 mg single dose cohorts were pooled as there was no apparent dose response between these two cohorts; In the 30 and 60 mg cohorts, wtHTT protein was preserved, which appears consistent with allele-selectivity; Increases in neurofilament light chain from baseline were observed in some participants; There were no clinically meaningful elevations in CSF white blood cell counts or protein that would indicate inflammation in the CNS; There were no meaningful changes in clinical outcome measures, although the dataset and duration were not sufficient to assess clinical effects. "These SELECT-HD data are the first to support the feasibility of allele-selective mHTT knockdown in the clinic - a precision approach enabled by our PRISM discovery and drug development platform," said Paul Bolno, MD, MBA, President and Chief Executive Officer at Wave Life Sciences. "SELECT-HD is the second clinical trial this year to demonstrate clinical translation of Wave's PN backbone chemistry modifications, as well as the impact of rational design through control of stereochemistry, increasing our conviction in our platform. We look forward to sharing data from our splicing clinical program in muscle - WVE-N531 for exon 53 skipping in Duchenne muscular dystrophy - in the fourth quarter of 2022."

ShowHide Related Items >><<
WVE Wave Life Sciences
$3.42 /

+0.19 (+5.88%)

WVE Wave Life Sciences
$3.42 /

+0.19 (+5.88%)

05/13/22 H.C. Wainwright
Wave Life Sciences price target lowered to $8 from $10 at H.C. Wainwright
03/03/22 Stifel
Wave Life Sciences price target lowered to $3 from $6 at Stifel
WVE Wave Life Sciences
$3.42 /

+0.19 (+5.88%)

Over a month ago
Hot Stocks
Wave Life Sciences expects cash to fund requirements to end of 2023 » 07:38
08/11/22
08/11
07:38
08/11/22
07:38
WVE

Wave Life Sciences

$2.55 /

+0.085 (+3.46%)

Wave expects that its…

Wave expects that its existing cash, cash equivalents and short-term investments will enable the company to fund its operating and capital expenditure requirements to the end of 2023.

ShowHide Related Items >><<
WVE Wave Life Sciences
$2.55 /

+0.085 (+3.46%)

WVE Wave Life Sciences
$2.55 /

+0.085 (+3.46%)

05/13/22 H.C. Wainwright
Wave Life Sciences price target lowered to $8 from $10 at H.C. Wainwright
03/03/22 Stifel
Wave Life Sciences price target lowered to $3 from $6 at Stifel
WVE Wave Life Sciences
$2.55 /

+0.085 (+3.46%)

Earnings
Wave Life Sciences reports Q2 EPS (62c) vs. (78c) last year » 07:38
08/11/22
08/11
07:38
08/11/22
07:38
WVE

Wave Life Sciences

$2.55 /

+0.085 (+3.46%)

Reports Q2 revenue $0.4M,…

Reports Q2 revenue $0.4M, consensus $3.83M. "At Wave, we are urgently working to advance our lead programs for the treatment of devastating genetic diseases. Since the start of the second quarter of 2022, we have achieved multiple important milestones, including positive target engagement data in our FOCUS-C9 clinical trial and the selection of our first RNA editing, or 'AIMer', development candidate, WVE-006 for the treatment of AATD," said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. "RNA editing is a novel therapeutic modality and Wave is leading this field with our AIMers. These RNA base editing therapeutics are being advanced with and without GalNAc conjugation and avoid the need for large, complex delivery vehicles, such as lipid nanoparticles or viral vectors. Our recent financing ensures we are well-capitalized to execute on several key milestones, including data announcements from three ongoing clinical trials and the advancement of WVE-006 into clinical development."

ShowHide Related Items >><<
WVE Wave Life Sciences
$2.55 /

+0.085 (+3.46%)

WVE Wave Life Sciences
$2.55 /

+0.085 (+3.46%)

05/13/22 H.C. Wainwright
Wave Life Sciences price target lowered to $8 from $10 at H.C. Wainwright
03/03/22 Stifel
Wave Life Sciences price target lowered to $3 from $6 at Stifel
WVE Wave Life Sciences
$2.55 /

+0.085 (+3.46%)

Over a quarter ago
Hot Stocks
Ra Capital Management increases passive stake in Wave Life Sciences » 16:50
06/21/22
06/21
16:50
06/21/22
16:50
WVE

Wave Life Sciences

$2.05 /

+0.09 (+4.59%)

Ra Capital Management…

Ra Capital Management disclosed an increased stake in Wave Life Sciences to 17.27M shares. The filing does not allow for activism. Shares of Wave Life Sciences are up 11.7% afterhours at $2.30.

ShowHide Related Items >><<
WVE Wave Life Sciences
$2.05 /

+0.09 (+4.59%)

WVE Wave Life Sciences
$2.05 /

+0.09 (+4.59%)

05/13/22 H.C. Wainwright
Wave Life Sciences price target lowered to $8 from $10 at H.C. Wainwright
03/03/22 Stifel
Wave Life Sciences price target lowered to $3 from $6 at Stifel
WVE Wave Life Sciences
$2.05 /

+0.09 (+4.59%)

Hot Stocks
Wave Life Sciences announces pricing of $70M underwritten offering » 09:05
06/14/22
06/14
09:05
06/14/22
09:05
WVE

Wave Life Sciences

$1.99 /

-0.16 (-7.44%)

Wave Life Sciences…

Wave Life Sciences announced the pricing of an underwritten offering of 25,464,483 of its ordinary shares at an offering price of $2.15 per ordinary share, and, to RA Capital Management, L.P. in lieu of ordinary shares, pre-funded warrants to purchase up to 7,093,656 ordinary shares at an offering price of $2.1499 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant. The per share offering price for the ordinary shares represents a premium of 7.5% over the closing price for Wave Life Sciences' ordinary shares on June 13, 2022. The pre-funded warrants contain a blocker provision which provides that they are only exercisable upon receipt of shareholder approval or if such exercise would not cause the aggregate number of ordinary shares or the combined voting power of total securities, in each case, beneficially owned by the holder to exceed 19.99% of the number of ordinary shares or total securities, respectively, outstanding immediately after giving effect to the exercise. Gross proceeds to Wave Life Sciences from the Offering are expected to be approximately $70.0 million, before deducting underwriting discounts and commissions and offering expenses. All of the securities in the Offering are being sold by Wave Life Sciences. The Offering is expected to close on or about June 16, 2022, subject to customary closing conditions. RA Capital and other notable growth and life science investors participated in the Offering.

ShowHide Related Items >><<
WVE Wave Life Sciences
$1.99 /

-0.16 (-7.44%)

WVE Wave Life Sciences
$1.99 /

-0.16 (-7.44%)

05/13/22 H.C. Wainwright
Wave Life Sciences price target lowered to $8 from $10 at H.C. Wainwright
03/03/22 Stifel
Wave Life Sciences price target lowered to $3 from $6 at Stifel
WVE Wave Life Sciences
$1.99 /

-0.16 (-7.44%)

Conference/Events
Wave Life Sciences management to meet with Mizuho » 04:55
05/25/22
05/25
04:55
05/25/22
04:55
WVE

Wave Life Sciences

$1.31 /

+0.035 (+2.75%)

Meeting to be held in…

Meeting to be held in Southeast Florida on May 25 hosted by Mizuho.

ShowHide Related Items >><<
WVE Wave Life Sciences
$1.31 /

+0.035 (+2.75%)

WVE Wave Life Sciences
$1.31 /

+0.035 (+2.75%)

05/13/22 H.C. Wainwright
Wave Life Sciences price target lowered to $8 from $10 at H.C. Wainwright
03/03/22 Stifel
Wave Life Sciences price target lowered to $3 from $6 at Stifel
WVE Wave Life Sciences
$1.31 /

+0.035 (+2.75%)

Conference/Events
Wave Life Sciences management to meet with Mizuho » 09:51
05/23/22
05/23
09:51
05/23/22
09:51
WVE

Wave Life Sciences

$1.18 /

-0.04 (-3.28%)

Meeting to be held in…

Meeting to be held in Southeast Florida on May 25 hosted by Mizuho.

ShowHide Related Items >><<
WVE Wave Life Sciences
$1.18 /

-0.04 (-3.28%)

WVE Wave Life Sciences
$1.18 /

-0.04 (-3.28%)

05/13/22 H.C. Wainwright
Wave Life Sciences price target lowered to $8 from $10 at H.C. Wainwright
03/03/22 Stifel
Wave Life Sciences price target lowered to $3 from $6 at Stifel
WVE Wave Life Sciences
$1.18 /

-0.04 (-3.28%)

Recommendations
Wave Life Sciences price target lowered to $8 from $10 at H.C. Wainwright » 06:15
05/13/22
05/13
06:15
05/13/22
06:15
WVE

Wave Life Sciences

$1.28 /

-0.19 (-12.93%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein lowered the firm's price target on Wave Life Sciences to $8 from $10 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
WVE Wave Life Sciences
$1.28 /

-0.19 (-12.93%)

WVE Wave Life Sciences
$1.28 /

-0.19 (-12.93%)

03/03/22 Stifel
Wave Life Sciences price target lowered to $3 from $6 at Stifel
05/19/21 Mizuho
Wave Life Sciences price target raised to $8 from $7 at Mizuho
WVE Wave Life Sciences
$1.28 /

-0.19 (-12.93%)

Hot Stocks
Wave Life Sciences expects cash to fund operations into Q2 of 2023 » 07:46
05/12/22
05/12
07:46
05/12/22
07:46
WVE

Wave Life Sciences

$1.47 /

-0.13 (-8.13%)

As of March 31, 2022,…

As of March 31, 2022, Wave had $111.7 million in cash, cash equivalents and short-term investments. As of December 31, 2021, Wave had $150.6 million in cash and cash equivalents. This decrease was mainly due to Wave's year-to-date net loss of $37.8 million. Wave expects that its existing cash, cash equivalents and short-term investments will enable the company to fund its operating and capital expenditure requirements into the second quarter of 2023.

ShowHide Related Items >><<
WVE Wave Life Sciences
$1.47 /

-0.13 (-8.13%)

WVE Wave Life Sciences
$1.47 /

-0.13 (-8.13%)

03/03/22 Stifel
Wave Life Sciences price target lowered to $3 from $6 at Stifel
05/19/21 Mizuho
Wave Life Sciences price target raised to $8 from $7 at Mizuho
WVE Wave Life Sciences
$1.47 /

-0.13 (-8.13%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.